Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
The present invention relates to methods for treating and preventing graft-versus-host disease (GVHD) and radiation-induced tissue damage or organ failure. More particularly, methods of the present invention comprise administering a therapeutically effective amount of mesenchymal stem cell-educated macrophages (MEMs) to a subject to treat or prevent GVHD, bone marrow failure, radiation-induced tissue damage or organ failure, or a condition associated with aberrant inflammation.
1. A method for treating bone marrow failure in a subject exposed to ionizing radiation, the method comprising administering to the subject a therapeutically effective amount of human IL-6 high, IL-10 high, IL-12 low, and TNF-α low mesenchymal stem cell-educated macrophages (MEMs), whereby the MEM-administered subject maintains production of white blood cells and platelets after exposure to ionizing radiation.
2. The method of claim 1 , wherein the ionizing radiation exposure is a consequence of radiation therapy or accidental radiation exposure.
3. The method of claim 1 , wherein the subject is exposed to ionizing radiation prior to administering MEMs.
4. The method of claim 1 , wherein the MEMs are administered in a pharmaceutical composition comprising MEMs and a pharmaceutically acceptable carrier.
5. The method of claim 1 , wherein the MEMs are administered by intravenous injection or by injection directly to a site of radiation exposure.
6. The method of claim 1 , wherein the therapeutically effective amount of MEMs is between about 1×10 6 cells/kilogram to about 10×10 6 cells/kilogram of body weight of the subject.
7. The method of claim 1 , wherein the MEMs are PD-L1 high and PD-L2 high.
8. The method of claim 1 , wherein the subject is exposed to a myeloablative dose of ionizing radiation.